Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/RET Fusion Cancer

Rare Cancers

RET Fusion Cancer Clinical Trials and Treatments

Also called RET fusion, RET rearrangement, RET fusion-positive NSCLC, RET fusion-positive cancer, RET-altered cancer

RET fusion cancers are caused by chromosomal rearrangements that join the RET gene (which encodes a receptor tyrosine kinase normally involved in cell growth and nervous system development) with a partner gene. The resulting fusion protein is constitutively active, driving cancer growth independent of normal signaling controls. The most common RET fusion partner in lung cancer is KIF5B, though many other partners have been identified.

In plain words, RET fusion cancers are a group of rare cancers where a gene called RET gets joined to another gene by mistake. This creates a faulty protein that makes cells grow out of control, and it is found in some lung, thyroid and other cancers.

Get an email when new RET Fusion Cancer trials open or the FDA decides. Get alerts

RET Fusion Cancer

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 3 studies with no phase, like observational studies, and 2 phase 4 studies following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Retevmo · Gavreto

RET Fusion Cancer has 2 FDA-approved medicines, 9 open or active clinical trials (6 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for RET Fusion Cancer

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about RET Fusion Cancer

RET fusions are most frequently found in non-small cell lung cancer (1-2% of cases) and papillary thyroid cancer (7-12% of cases, higher in pediatric patients), and less commonly in other tumor types including colorectal, breast, and other cancers. Because RET fusions are actionable across tumor types, comprehensive genomic profiling is essential for identifying these patients.

Keep reading about RET Fusion Cancer

Selective RET inhibitors have transformed treatment. Selpercatinib (Retevmo, Eli Lilly) received regular FDA approval for RET fusion-positive NSCLC in September 2022. Its label now also reports the Phase 3 LIBRETTO-431 trial, in which first-line Retevmo kept the cancer from growing for a median 24.8 months against 11.2 months on chemotherapy with pembrolizumab.

On July 14, 2026 the FDA gave selpercatinib traditional approval for RET fusion-positive solid tumors of any type in adults and children 2 and older whose cancer grew after earlier treatment or who have no good alternative. In the 75 patients with tumors other than lung and thyroid cancer, 47% responded. Pralsetinib (Gavreto) received regular approval for RET fusion-positive NSCLC in August 2023 and also has accelerated approval for RET fusion-positive thyroid cancer in people 12 and older. Its label added a boxed warning for serious infections in December 2025.

These selective inhibitors have largely replaced older multikinase inhibitors and chemotherapy for RET fusion-positive cancers.

What are the symptoms of RET Fusion Cancer?

These are common symptoms of RET Fusion Cancer, and how strong they are varies from person to person.

  • Symptoms depend on the tumor type and location
  • For lung cancer: persistent cough, shortness of breath, chest pain, coughing up blood
  • For thyroid cancer: a neck lump, hoarseness, difficulty swallowing
  • Fatigue and unexplained weight loss
  • Bone pain, headaches, or neurological symptoms if the cancer has spread
  • Some RET fusion cancers are discovered incidentally on imaging

Who gets RET Fusion Cancer?

RET fusions in NSCLC tend to occur in younger patients (median age ~60), never-smokers or light smokers, and are slightly more common in women, though they can occur in anyone. RET fusion-positive papillary thyroid cancer can occur at any age.

No clear ethnic predisposition is established, though detection rates vary by how commonly genomic testing is performed. The fusion is a somatic (acquired) event, not inherited, distinguishing it from germline RET mutations that cause hereditary medullary thyroid cancer.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for RET Fusion Cancer?

There are currently 2 FDA-approved medications for RET Fusion Cancer.

pralsetinib
Rigel Pharmaceuticals, Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for RET Fusion Cancer treatment

Charity funds and drugmaker programs for RET Fusion Cancer, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for RET Fusion Cancer, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for RET Fusion Cancer

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

The RET gene page lists every condition Orphanet links to the gene and the open trials that name it.

Finding labs...

Trusted RET Fusion Cancer resources

Reputable organizations and medical references for learning more about RET Fusion Cancer, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for RET Fusion Cancer

Use this RET Fusion Cancer clinical trial finder to see the 6 studies recruiting patients and 3 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 8 test a treatment and 1 is an observational study or registry; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

9 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 2Recently updatedNCT01639508

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Intervention: Cabozantinib

Sponsor: Memorial Sloan Kettering Cancer Center · Exelixis

The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.

Ages 18 Years+
Started Jul 2012Updated 3 weeks agoEst. Jul 2027 (~8 months)
RecruitingTreatment trialPhase 3Recently updatedNCT07809256

A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

Intervention: lenvatinib pembrolizumab

Sponsor: EuroCityClinic LLC

This interventional study will evaluate the effectiveness, safety, and tolerability of pembrolizumab in combination with lenvatinib in adults with metastatic non-small cell lung cancer (NSCLC) who have a confirmed RET gene rearrangement and whose disease has progressed after one or more previous systemic treatments.

Ages 18 Years+1 location
Expected to start Sep 2026Updated 2 months agoEst. Aug 2028 (~1y 9m)
RecruitingTreatment trialPhase 4Updated a few months agoNCT07704658

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

Intervention: Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

Sponsor: Rigel Pharmaceuticals

An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors

Ages 18 Years+2 locations
Started Mar 2026Updated 3 months agoEst. Jul 2027 (~8 months)
RecruitingTreatment trialPhase 2Updated a few months agoNCT06458036

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Intervention: Selpercatinib Monotherapy, 131I Therapy

Sponsor: Children's Hospital of Philadelphia · Eli Lilly and Company

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung meta...

Ages 2 Years to 25 Years4 locations
Started Jul 2024Updated 4 months agoEst. Nov 2030 (~3y 11m)
Not yet recruitingTreatment trialNo updates in a whileNCT07418879

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Intervention: Pralsetinib, Leucogen

Sponsor: Fudan University

This study is a single-arm, multicenter real-world clinical study designed to evaluate the safety and efficacy of Leucogen (a leukocyte-increasing agent) as a prophylactic treatment in patients with RET fusion-positive non-small cell lung cancer (NSCLC) who are being treated with Pralsetinib.

Ages 18 Years+
Expected to start Feb 2026Updated 9 months agoEst. Dec 2027 (~1y 1m)
Find RET Fusion Cancer trials near you, ranked by distance →
Active trial locations13 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+5 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 2
Phase 3
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about RET Fusion Cancer trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a RET Fusion Cancer foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

RET Fusion Cancer patient communities

Facebook groups, Reddit communities and YouTube channels where RET Fusion Cancer patients, caregivers and advocacy groups talk.

Companies developing RET Fusion Cancer treatments

Drugmakers that list RET Fusion Cancer in their rare disease portfolio, 4 in all.

Questions people ask about RET Fusion Cancer